Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.46 |
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 4/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29154389 | 0.75 | MEN1 (0.41) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL13684679 | 0.74 | TDP1 (0.49) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL24289281 | 0.74 | MEN1 (0.39) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL12379793 | 0.74 | HTR2A (0.41) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL14685789 | 0.73 | GAA (0.39) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL25506285 | 0.72 | MEN1 (0.47) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL11756149 | 0.70 | MAPT (0.71) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL13892507 | 0.70 | MEN1 (0.37) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL21669403 | 0.70 | MAPT (0.41) | CREBBPBRD4MEN1KMT2AGAA | |
| SCHEMBL16510220 | 0.70 | MAPT (0.41) | CREBBPBRD4MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295163-A1 | TETRACYCLIC DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| WO-2023113561-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2023-06-22 | — | — | WO | disclosed |
| EP-3442955-B1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | US HEALTH (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-1506214-B1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARM INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2005087750-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | CREBBP 1448/4885BRD4 807/4885MEN1 3147/4885 |
| US-20230295163-A1 | TETRACYCLIC DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | KRAS, NRAS, RHOA | CREBBP 1582/4885BRD4 3355/4885MEN1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.